In contrast to the increasingly targeted drugs for patients with lung adenocarcinoma involving EGFR, ALK, ROS1, RET, BRAF, MET and NTRK, SCLC is still perceived and treated as a single disease, a “homogenous” entity without clinically relevant molecular subtypes. Here, BRAF is linked to small cell lung carcinoma.